Scarica l'app Stockscreener
29.00
1.02%
-0.30
Dopo l'orario di chiusura:
29.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$29.30
Aprire:
$30.08
Volume 24 ore:
10.03M
Relative Volume:
0.81
Capitalizzazione di mercato:
$6.77B
Reddito:
$2.35B
Utile/perdita netta:
$128.37M
Rapporto P/E:
55.54
EPS:
0.5221
Flusso di cassa netto:
$57.42M
1 W Prestazione:
-1.43%
1M Prestazione:
+1.12%
6M Prestazione:
+51.52%
1 anno Prestazione:
-49.89%
Intervallo 1D:
$28.55
$30.61
Intervallo di 1 settimana:
$28.30
$31.03
Portata 52W:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.00 | 6.86B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Iniziato | JP Morgan | Overweight |
| 2026-03-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Aggiornamento | Citigroup | Sell → Neutral |
| 2026-03-09 | Aggiornamento | Needham | Hold → Buy |
| 2026-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-01-12 | Iniziato | Evercore ISI | In-line |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Telehealth sector outlook: Doximity, Hims & Hers, and Teladoc compared By Investing.com - Investing.com Canada
Form 144 Hims & Hers Health For: 1 October By Investing.com - Investing.com Canada
Kaplan Fox Notifies Investors of Hims & Hers Health, Inc. (NYSE - The National Law Review
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming DeadlinesHIMS - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Hims & Hers appoints medical officers for UK and Australia - Investing.com UK
Rural Access, Digital Health, and What's Next with Matt Vickers, Chief Medical Officer of Hims Australia - Hims & Hers Newsroom
Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership - HIMS investor relations
Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership - The Joplin Globe
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Hims & Hers Goes GlobalRenewed Growth Prospects With Margin Risks (NYSE:HIMS) - Seeking Alpha
HIMS ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before November 2, 2026 Deadline - PR Newswire
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.8% R - GuruFocus
Hims & Hers: U.S. Revenue Reacceleration Is Reassuring, And Valuation Compression Is Compelling (Upgrade) - Seeking Alpha
Hims Stock Reclaims $30 and Attempts Breakout but Faces $35 Test - FXLeaders
Hims & Hers Health Rallies as Investors Appear to Reassess Recent Selloff - Quiver Quantitative
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law - GlobeNewswire
HIMS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Hims Inves - The National Law Review
Shareholders who lost money in shares of acquired Hims & - GlobeNewswire
HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Hims & Hers Health, Inc. Securities Fraud Class Action - GlobeNewswire
Robbins LLP Urges HIMS Stockholders to Contact the Firm for Information About the Hims & Hers Health, Inc. Class Action Lawsuit - PR Newswire
Deadline Alert: Hims & Hers Health, Inc. (HIMS) - GlobeNewswire
Hims & Hers Health (HIMS) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline - PR Newswire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
INVESTOR ALERT: Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
What Do Today's Market Moves Mean for Hims & Hers Health (NYSE:HIMS)? - Kalkine Media
ROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers - GlobeNewswire
Form 144 Hims & Hers Health For: 27 September By Investing.com - Investing.com Nigeria
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit - Morningstar
Can Hims & Hers Health (HIMS) Stay Cheap As Sales Face Scrutiny? - Yahoo Finance
Form 4 Hims Hers Health Inc For: 26 September By Investing.com - Investing.com South Africa
Hims & Hers CFO Okupe sells $876,846 of HIMS stock - Investing.com
Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform - Yahoo Finance
Kaplan Fox Advises Hims & Hers Health, Inc. (NYSE: HIMS) Investor - The National Law Review
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - morningstar.com
2 Reasons to Like HIMS (and 1 Not So Much) - Yahoo Finance
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire
HIMS Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 DeadlineHIMS - TMX Newsfile
Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation - HIT Consultant
Hims & Hers Health Inc (HIMS) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HI - The National Law Review
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks - MarketBeat
10 Health Care Stocks Whale Activity In Today’s Session - benzinga.com
Hims & Hers (HIMS) Shareholder Alert: Investigation of Potential Fiduciary Duty BreachesKehoe Law Firm, P.C. - The National Law Review
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HIMS) With Significant Losses to a Securities Class Action Deadline on November 2, 2026 - Barchart.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):